1. Home
  2. RNAC vs SGHT Comparison

RNAC vs SGHT Comparison

Compare RNAC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$5.84

Market Cap

243.0M

Sector

Health Care

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$4.48

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAC
SGHT
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.0M
235.0M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
RNAC
SGHT
Price
$5.84
$4.48
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$34.00
$9.08
AVG Volume (30 Days)
145.8K
180.9K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
$2,797,000.00
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.60
$3.11
52 Week High
$14.56
$9.24

Technical Indicators

Market Signals
Indicator
RNAC
SGHT
Relative Strength Index (RSI) 39.56 46.25
Support Level N/A $3.34
Resistance Level $7.95 $5.25
Average True Range (ATR) 0.74 0.31
MACD -0.14 -0.09
Stochastic Oscillator 4.27 26.11

Price Performance

Historical Comparison
RNAC
SGHT

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: